Edgar Filing: NOVAVAX INC - Form 4

NOVAVA Form 4	X INC									
March 17, 2								PPROVAL		
FOR	M 4 UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								
if no lo subject Section Form 4 Form 5 obligat may co	to 16. or Filed put ions Section 17/	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Erck Stanley C			uer Name an d AVAX IN		C	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD			3. Date of Earliest Transaction (Month/Day/Year) 03/15/2016			X Director 10% Owner X Officer (give title Other (specify below) below) President and CEO				
GAITHER	f Amendment, Date Original d(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(State)	(7:)			a	Person				
1.Title of Security (Instr. 3)	2. Transaction Date	- 14	3. Transactio Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4	es (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	of, or Beneficia 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Ro	eport on a separate line	e for each class of so	ecurities bene	Person inform require	ns who rest ation cont ed to resp ys a curre	or indirectly. spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) E	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise	a	any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: NOVAVAX INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	\$ 4.99	03/15/2016		А		900,000		(1)	03/05/2026	Common Stock	900,000

Reporting Owners

Reporting Owner Name / Address	Relationships							
, of the second s	Director	10% Owner	Officer	Other				
Erck Stanley C C/O NOVAVAX, INC. 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878	Х		President and CEO					
Signatures								
/s/ John A. Herrmann III, Attorney-in-Fact		03/17	//2016					

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan vest on the first
 (1) anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.